Approval sought to give youngest vaccine
Moderna asks FDA to clear kids under 6 for COVID-19 shots
Moderna is seeking to be the first to offer COVID19 vaccine for the youngest American children, as it asked the Food and Drug Administration on Thursday to clear low-dose shots for babies, toddlers and preschoolers.
Frustrated families are waiting impatiently for a chance to protect the nation’s youngest children kids as all around them people shed masks and other public health precautions — even though highly contagious coronavirus mutants continue to spread. Already about three-quarters of children of all ages show signs they’ve been infected at some point during the pandemic.
Moderna submitted data to the Food and Drug Administration that it hopes will prove two low-dose shots can protect children younger than 6 — although the effectiveness wasn’t nearly as high in kids tested during the omicron surge as earlier in the pandemic.
“There is an important unmet medical need here with these youngest kids,” said Dr. Paul Burton, Moderna’s chief medical officer. Two kid-size shots “will safely protect them. I think it is likely that over time they will need additional doses. But we’re working on that.”
Moderna said two kid doses were about 40% to 50% effective at preventing symptomatic COVID19, not a home run but for many parents, any protection would be better than none.
That effectiveness is “less than optimal. We were hoping for better efficacy but this is a first step,” said Dr. Nimmi Rajagopal of Cook County Health in Chicago. She’s anxiously awaiting vaccinations for her youngest patients and her own 3-year-old son who’s ready to enter preschool.
“It gives me such peace of mind to know that hopefully by fall I’ll get him in school and he’ll be fully vaccinated,” she said.
Now, only children ages 5 or older can be vaccinated in the U.S., using rival Pfizer’s vaccine, leaving 18 million younger tots unprotected.
Moderna’s vaccine isn’t the only one in the race. Pfizer is soon expected to announce if three of its even smaller-dose shots work for the youngest kids, months after the disappointing discovery that two doses weren’t quite strong enough.
Whether it’s one company’s shots or both, FDA vaccine chief Dr. Peter Marks said the agency will “move quickly without sacrificing our standards” in deciding if tot-size doses are safe and effective.
While questions are swirling about what’s taking so long, Marks pointedly told lawmakers earlier this week that the FDA can’t evaluate a product until a manufacturer completes its application. In a statement Thursday, the FDA said it will schedule a meeting to publicly debate Moderna’s evidence with its independent scientific advisers but that the company still must submit some additional data. Moderna expects to do so next week.
“It’s critically important that we have the proper evaluation so that parents will have trust in any vaccines that we authorize,” Marks told a Senate committee.
If FDA clears vaccinations for the youngest, next the Centers for Disease Control and Prevention would have to recommend who needs them — all such children or just those at higher risk from COVID-19.
“It’s very important to get the youngest children vaccinated” but “moving quickly doesn’t mean moving sloppily,” said Dr. Philip Landrigan, a pediatrician and public health expert at Boston College. FDA must “see if it’s safe. They need to see if it’s effective. And they need to do so swiftly. But they won’t cut corners.”
The FDA will face some complex questions.
In a study of 6,700 kids ages 6 months through 5 years, two Moderna shots — each a quarter of the regular dose — triggered high levels of virus-fighting antibodies, the same amount proven to protect young adults, Burton said. There were no serious side effects, and the shots triggered fewer high fevers than other routine vaccinations.
But depending on how researchers measured, the vaccine proved at best about 51% effective at preventing COVID-19 cases in babies and toddlers and about 37% effective in the 2- to 5-yearolds. Burton blamed the omicron variant’s ability to partially evade vaccine immunity, noting that unboosted adults showed similarly less effectiveness against milder omicron infections. While no children became severely ill during the study, he said high antibody levels are a proxy for protection against more serious illness — and the company will test a child booster dose.
“That’s not totally out of the realm of what we would have expected,” said Dr. Bill Muller of Northwestern University, who helped with Moderna’s child studies. “Down the road I would anticipate it’s going to be a three-shot series.”